A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge

He, Xiangchuan; Ding, Longfei; Cao, Kangli; Peng, Haoran; Gu, Cheng; Li, Yutang; Li, Duoduo; Dong, Lanlan; Hong, Xiujing; Wang, Xiangwei; Fu, Mao; Qiu, Changjian; Zhu, Cuisong; Zhang, Ziling; Song, Shu; Wang, Chenguang; Jiang, Zhengfan; Xie, Youhua; Qi, Zhongtian; Zhao, Chen; Zhao, Ping; Zhang, Xiaoyan; Xu, Jianqing

doi:10.1080/22221751.2021.1957400

Cited by 6 publications

(7 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, the combination of multiple transgenic hACE2-expressing mouse models under various promoters, adenovirus-based methods for transduction of multiple mouse strains with hACE2, mouse-adapted SARS-CoV-2 strains, and the susceptibility of mice to emerging VOC has resulted in laboratory mice becoming highly useful models for SARS-CoV-2 infection studies and efficacy testing of vaccines and therapeutics [ 220 , 221 , 222 , 223 , 224 ].…”

Section: Main Textmentioning

confidence: 99%

Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals

Meekins

Gaudreault

Richt

2021

Viruses

View full text Add to dashboard Cite

SARS-CoV-2 is the etiological agent responsible for the ongoing COVID-19 pandemic, which continues to spread with devastating effects on global health and socioeconomics. The susceptibility of domestic and wild animal species to infection is a critical facet of SARS-CoV-2 ecology, since reverse zoonotic spillover events resulting in SARS-CoV-2 outbreaks in animal populations could result in the establishment of new virus reservoirs. Adaptive mutations in the virus to new animal species could also complicate ongoing mitigation strategies to combat SARS-CoV-2. In addition, animal species susceptible to SARS-CoV-2 infection are essential as standardized preclinical models for the development and efficacy testing of vaccines and therapeutics. In this review, we summarize the current findings regarding the susceptibility of different domestic and wild animal species to experimental SARS-CoV-2 infection and provide detailed descriptions of the clinical disease and transmissibility in these animals. In addition, we outline the documented natural infections in animals that have occurred at the human–animal interface. A comprehensive understanding of animal susceptibility to SARS-CoV-2 is crucial to inform public health, veterinary, and agricultural systems, and to guide environmental policies.

show abstract

Section: Main Textmentioning

confidence: 99%

Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals

Meekins

Gaudreault

Richt

2021

Viruses

View full text Add to dashboard Cite

show abstract

“…S16d ). Compared to the mean ID 50 titer of convalescent patient sera from our previous work 36 , the neutralizing activity of the antiserum of monkeys vaccinated with CoVac501 was comparable to that of convalescent patient sera. However, the protective effect of CoVac501 was notably decreased for neutralizing the B.1.351 (Beta) variant (Fig.…”

Section: Resultsmentioning

confidence: 52%

“…Pseudovirus neutralization assays were performed as in our previous work 36 . In brief, serum samples were serially diluted in medium after heat inactivation and then mixed with 50 μL of diluted pseudovirus.…”

Section: Methodsmentioning

confidence: 99%

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

et al. 2022

Self Cite

View full text Add to dashboard Cite

Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains immunodominant peptides screened from the receptor-binding domain (RBD) and is fully chemically synthesized. It has been formulated in an optimized nanoemulsion formulation and is stable at 40 °C for 1 month. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple RBD mutations, SARS-CoV-2 original strain, and variants (B.1.1.7 and B.1.617.2). Specific peptides booster immunization against the B.1.351 variant has also been shown to be effective in improving protection against B.1.351. Meanwhile, CoVac501 elicited the increase of memory T cells, antigen-specific CD8+ T-cell responses, and Th1-biased CD4+ T-cell immune responses in NHPs. Notably, at an extremely high SARS-CoV-2 challenge dose of 1 × 107 TCID50, CoVac501 provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.

show abstract

“…SARS-CoV-2 spike (S) protein specific memory B cells detected in recovered individuals are considered to be related to virus neutralization and have protective value [ 46 , 47 , 48 ]. For this reason, memory B cells are considered as a key component of long-lived immunity against SARS-CoV-2 infection [ 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain

Wang

Liu

et al. 2023

Pathogens

View full text Add to dashboard Cite

In the past few years, the continuous pandemic of COVID-19 caused by SARS-CoV-2 has placed a huge burden on public health. In order to effectively deal with the emergence of new SARS-CoV-2 variants, it becomes meaningful to further enhance the immune responses of individuals who have completed the first-generation vaccination. To understand whether sequential administration using different variant sequence-based inactivated vaccines could induce better immunity against the forthcoming variants, we tried five inactivated vaccine combinations in a mouse model and compared their immune responses. Our results showed that the sequential strategies have a significant advantage over homologous immunization by inducing robust antigen-specific T cell immune responses in the early stages of immunization. Furthermore, the three-dose vaccination strategies in our research elicited better neutralizing antibody responses against the BA.2 Omicron strain. These data provide scientific clues for finding the optimal strategy within the existing vaccine platform in generating cross-immunity against multiple variants including previously unexposed strains.

show abstract

A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge

Abstract: A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challengeOne Sentence Summary: A novel human cell-based vaccine, K562-S, elicit robust and protective antibody responses against SARS-CoV-2 in pre-clinical models.

Cited by 6 publications

References 57 publications

Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals

Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain

Contact Info

Product

Resources

About